| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Experimental Immunobiology, Wellcome Research Laboratories, Beckenham, Kent BR3 3BS, England [M. T. S.], and Trudeau Institute, Inc., Saranac Lake, New York 12983 [S. L. W.]
The effects of 14 weekly injections, s.c. or i.v., of "human equivalent" doses (5.25 mg/sq m) of Corynebacterium parvum (CP) in mice have been compared. Both s.c. and i.v. CP caused significant splenomegaly and antibody to CP, but stimulation was considerably greater after i.v. CP. Delayed hypersensitivity levels to CP were similar after s.c. and i.v. injection. T-cell competence, as judged by phytohemagglutinin reactivity and delayed hypersensitivity to sheep cells, was unimpaired after s.c. CP and augmented by i.v. CP. Activated peritoneal macrophages capable of nonspecifically inhibiting tumor growth in vitro were detected only after i.v. CP, and in vivo resistance to tumor cell challenge was greater after CP administered i.v. than s.c.
1 To whom requests for reprints should be addressed.
Received 10/28/75. Accepted 12/30/75.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |